Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROSERPINE PLUS (R-H-H) vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hydrochlorothiazide: Not metabolized, excreted unchanged in urine. Reserpine: Metabolized in the liver via hydrolysis and conjugation. Hydralazine: Acetylation in the liver via N-acetyltransferase (NAT2).
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Hydroflumethiazide: 70% (albumin); reserpine: 96%; hydralazine: 87% (albumin and alpha-1 acid glycoprotein).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Hydroflumethiazide: 3.6 L/kg; reserpine: 10-20 L/kg; hydralazine: 1.6 L/kg (central) and 2.7 L/kg (total).
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: hydroflumethiazide 70-75%; reserpine 50-60%; hydralazine 30-50% (first-pass metabolism).
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 1 tablet orally once daily; monitor electrolytes. No adjustment needed for Cr Cl >50 m L/min.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B: use with caution; reduce dose to 1 tablet orally once daily and monitor for encephalopathy.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start with 1 tablet orally once daily; titrate slowly. Monitor for orthostatic hypotension, electrolyte imbalances, and CNS effects. Avoid use in patients with depression.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
Reserpine: May cause mental depression, especially in patients with a history of depression. Discontinue at first signs of depression.
None.
Hydrochlorothiazide: Electrolyte imbalance, hyperglycemia, hyperuricemia, lupus exacerbation. Reserpine: Mental depression, peptic ulcer, bradycardia. Hydralazine: Drug-induced lupus, tachycardia, myocardial ischemia, peripheral neuritis.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Reserpine: Hypersensitivity, history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma. Hydralazine: Hypersensitivity, mitral valve rheumatic heart disease, coronary artery disease. Hydrochlorothiazide: Anuria, hypersensitivity to sulfonamides, severe renal failure.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) due to the potassium-sparing effect of the combination? Note: Actually HYDROSERPINE PLUS contains hydrochlorothiazide which is potassium-wasting; reserpine and hydralazine do not affect potassium significantly. Thus, potassium supplementation may be needed; monitor potassium levels. Limit sodium intake to control blood pressure. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) due to reserpine's potential to cause hypertensive crisis? Reserpine is not a MAOI, but caution with high-tyramine foods is advised.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not teratogenic in animal studies. Second and third trimesters: Hydrochlorothiazide may cause fetal electrolyte disturbances and thrombocytopenia; reserpine may cause neonatal bradycardia and hypotension; hydralazine may cause fetal hypotension and reflex tachycardia.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Hydrochlorothiazide is excreted in breast milk in low concentrations (M/P ratio 0.6); reserpine is excreted (M/P ratio unknown, but may cause galactorrhea and infant sedation); hydralazine is excreted in low amounts (M/P ratio not well defined). Theoretical risk of hypotensive effects in infants. Caution recommended.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No specific dose adjustments have been established for the combination; however, increased plasma volume and renal clearance in pregnancy may reduce efficacy, potentially requiring dose increase or alternative therapy. Individualize based on blood pressure response and avoid volume depletion.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Hydralazine and hydrochlorothiazide can cause lupus-like syndrome; monitor for arthralgias, rash, and fever. Reserpine depletes catecholamines, leading to potential sedation and depression; use with caution in patients with history of mood disorders. Check serum potassium and uric acid levels due to thiazide component.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying down to prevent dizziness.,Avoid driving or operating machinery until you know how this drug affects you.,Report any unusual weight gain, swelling, or shortness of breath.,Contact your doctor if you experience joint pain, fever, or rash.,Do not stop taking this medicine abruptly; it may cause blood pressure to rise.,Limit alcohol consumption as it can increase dizziness and drowsiness.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROSERPINE PLUS (R-H-H) vs ALDOCLOR-150, answered by our medical review team.
HYDROSERPINE PLUS (R-H-H) is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROSERPINE PLUS (R-H-H) and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROSERPINE PLUS (R-H-H) is: 1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROSERPINE PLUS (R-H-H) and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROSERPINE PLUS (R-H-H) is classified as Category C. First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not terat. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.